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Background: The transcription factor GATA3 is a favorable prognostic indicator in estrogen receptor-α (ERα)-positive
breast tumors in which it participates with ERα and FOXA1 in a complex transcriptional regulatory program driving
tumor growth. GATA3 mutations are frequent in breast cancer and have been classified as driver mutations. To elucidate
the contribution(s) of GATA3 alterations to cancer, we studied two breast cancer cell lines, MCF7, which carries a
heterozygous frameshift mutation in the second zinc finger of GATA3, and T47D, wild-type at this locus.
Methods: Immunofluorescence staining and subcellular fractionation were employed to verify cellular
localization of GATA3 in T47D and MCF7 cells. To test protein stability, cells were treated with translation
inhibitor, cycloheximide or proteasome inhibitor, MG132, and GATA3 abundance was measured over time using
immunoblot. GATA3 turn-over in response to hormone was determined by treating the cells with estradiol or
ERα agonist, ICI 182,780. DNA binding ability of recombinant GATA3 was evaluated using electrophoretic mobility
shift assay and heparin chromatography. Genomic location of GATA3 in MCF7 and T47D cells was assessed by
chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-seq).
Results: GATA3 localized in the nucleus in T47D and MCF7 cells, regardless of the mutation status. The
truncated protein in MCF7 had impaired interaction with chromatin and was easily released from the nucleus.
Recombinant mutant GATA3 was able to bind DNA to a lesser degree than the wild-type protein. Heterozygosity
for the truncating mutation conferred protection from regulated turnover of GATA3, ERα and FOXA1 following
estrogen stimulation in MCF7 cells. Thus, mutant GATA3 uncoupled protein-level regulation of master regulatory
transcription factors from hormone action. Consistent with increased protein stability, ChIP-seq profiling identified
greater genome-wide accumulation of GATA3 in MCF7 cells bearing the mutation, albeit with a similar distribution
across the genome, comparing to T47D cells.
Conclusions: We propose that this specific, cancer-derived mutation in GATA3 deregulates physiologic protein
turnover, stabilizes GATA3 binding across the genome and modulates the response of breast cancer cells to
estrogen signaling.
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Accumulation of somatic mutations is responsible for de-
velopment of breast cancer, as 85% of affected women have
no family history of the disease (http://www.breastcancer.
org). Nearly 31,000 point mutations and small insertions or
deletions (indels) in at least 170 previously reported and
novel cancer genes have been implicated in the develop-
ment of breast tumors [1]. Whole exome sequencing
places the zinc-finger transcription factor GATA3, with
a 10% frequency of alterations, among the top three (to-
gether with p53 (TP53) and phosphoinositide-3-kinase
(PIK3CA)) mutation driver genes in breast cancer [1,2].
On the basis of mutation pattern, Vogelstein and col-
leagues [3] classify GATA3 as a tumor suppressor. Indeed,
in mice xenograft studies GATA3 was positively correlated
with survival and lack of metastasis [4]. However, it has
been also postulated that GATA3 defines a distinct class
of cancer genes that are differentiation factors rather than
conventional tumor suppressor genes, which affect the
malignant phenotype by enforcing differentiation [5-7].
Specifically, conditional deletion of GATA3 is not suffi-
cient to promote malignant progression, and is not toler-
ated in early tumors [5,8]. GATA3 has been shown in
mouse model of breast cancer to maintain tumor differ-
entiation, suppress dissemination and inhibit metastasis
[8,9]. While GATA3 has been intensively studied in the
immune system, where it functions in development and
differentiation of T-cells [10], it is also an essential regu-
lator of mammary-gland morphogenesis and luminal-
cell differentiation [11,12]. It is frequently up-regulated
in breast cancer and has been identified as a favorable
prognosis marker [13]. GATA3 is involved in a positive
cross-regulatory loop with estrogen receptor-α (ERα)
[14] where they both serve as markers for luminal breast
cancer [15,16].
The interplay of GATA3, ERα, and FOXA1 has been a
topic of multiple functional genomic studies. Kong and
co-authors defined an enhanceosome consisting of co-
localizing ERα-FOXA1-GATA3 which recruits RNA Pol
II and p300 [17]. The triple conjoint binding sites are
highly represented at the locations involved in frequent
long-range chromatin interactions and associated with
genes that are most responsive to estrogen. In turn, Theo-
dorou and colleagues silenced GATA3 and observed a
global redistribution of FOXA1 and p300 cofactors, and
active histone marks prior to estrogen stimulation [18].
These global genomic changes alter the ERα-binding
profile that subsequently occurs following estrogen
treatment, demonstrating that GATA3 can act upstream
of FOXA1 in mediating ERα binding by modulating en-
hancer composition.
Haploinsufficiency of GATA3 in humans results in HDR
syndrome, a rare condition inherited as autosomal domin-
ant trait, characterized by hypoparathyroidism, deafness,and renal dysplasia [19]. Genomic alteration of GATA3 as-
sociated with HDR syndrome include large deletions re-
moving the entire gene and flanking sequences, splice site
mutations, indels, and point mutations resulting most
often in frameshifts [20]. Mutations in HDR patients local-
ized in the second zinc finger (ZnF2) of GATA3 or adja-
cent amino acids result in loss of DNA binding, whereas
those in the first zinc finger (ZnF1) lead to loss of inter-
action with a cofactor, FOG2, or altered DNA-binding af-
finity [20,21]. Interestingly, while HDR GATA3 mutations
are spread throughout the gene, breast cancer mutations
cluster around ZnF2 and C-terminal domain [1,22,23].
Analysis of six different heterozygous GATA3 mutations
from eight breast tumors has demonstrated loss or reduc-
tion of DNA binding ability, aberrant nuclear localization,
decrease in transcription activation, and alterations in in-
vasiveness, but not proliferation [22]. However, it is un-
clear how those functional modifications contribute to the
oncogenesis process in breast cancer.
The aim of the present study was to evaluate the effect
of a breast cancer-specific mutation in GATA3 on bio-
chemical properties and genomic location of the protein.
We utilized two luminal breast cancer cell lines, MCF7
harboring a heterozygous frameshift mutation in ZnF2,
and T47D carrying wild-type version GATA3. We ob-
served that mutant GATA3 was expressed at elevated
levels relative to wild-type protein and it accumulated in
nuclei. Surprisingly, the mutation led to enhanced protein
stability following challenge with estrogen receptor agon-
ist or antagonist. This increased stability led to increased
levels, but not to global redistribution, of GATA3 binding
in the genome as determined by ChIP-seq. The data
collectively support the hypothesis that the carboxyl
terminus of GATA3 contains protein regulatory infor-
mation that ensures appropriate turnover following lig-
and binding by ERα.
Methods
Cell culture
Human breast carcinoma cell lines MCF-7 and T47D
were obtained from the American Type Culture Collec-
tion (Manassas, VA, USA) and cultured in DMEM/F-12
medium supplemented with 10% FBS at 37°C in 5% CO2.
Protein stability was evaluated in the normal growth
medium and cells were treated with 1 μM cycloheximide
(CHX) and/or 1 μM MG132 (MG) for up to eight hours.
For estrogen starvation assays, cells were grown for
72 hours in MEM medium containing 5% FBS and then
for 24 hours in phenol red-free MEM supplemented with
5% charcoal-dextran stripped FBS. Cells were treated with
50 nM 17β-estradiol (E2) for 24 hours. The effect of ERα
inhibitor, ICI 182,780 (ICI) was tested in normal growth
medium. ICI was added at 100 nM concentration and cells
were harvested 24 hours later. MG (EMD Biosciences,
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man Chemical, Ann Arbor, MI, USA) in water, ICI (Tocris
Bioscience Ellisville, MS, USA) and E2 (Sigma, St. Louis,
MO, USA) in ethanol.Subcellular fractionation
Cells were grown in 10 cm tissue culture dishes until they
were 70-80% confluent. The cells were washed with PBS,
collected by scraping and resuspended in buffer contain-
ing 0.15 M NaCl, 10 mM HEPES, pH 7.4, 1.5 mM MgCl2,
10 mM KCl, 0.5% NP-40, 0.5 mM DTT and protease
inhibitors. The cytoplasmic fraction was separated by
centrifugation at 2500 rpm for 10 min. The pellet was
resuspended in nuclear extraction buffer containing 0.1,
0.2, 0.4 or 0.8 M NaCl, 25 mM HEPES, pH 7.4, 0.15 mM
spermidine, 0.5 mM spermine, 5% glycerol, 1 mM EDTA
and protease inhibitors. Samples were rotated for 30 min
at +4°C and spun down in Optima Max centrifuge
(Beckman Coulter, Brea, CA, USA) at 38,000 rpm for
45 min at +4°C. The nuclear fraction was collected and
remaining pellet was dissolved in lysis buffer (8 M urea,
1% SDS, 0.125 M Tris, pH 6.8).Immunoblotting
Whole cell lysates were obtained using 8 M urea lysis
buffer (8 M urea, 1% SDS, 0.125 M Tris, pH 6.8). Protein
extracts (15 μg) were resolved on SDS–PAGE gels and
immunoblotted using the following antibodies: GATA3
(D13C9; Cell Signaling Technology, Danvers, MA), FOXA1
(ab23738; Abcam, Cambridge, MA, USA), ERα (sc-543;
Santa Cruz Biotechnology, Santa Cruz, CA, USA) and actin
(ab8226; Abcam). Signal intensity was analyzed using
rectangular volume tool in Quantity One Analysis Soft-
ware (Bio-Rad, Hercules, CA, USA) with global back-
ground subtraction.Immunofluorescence staining
Cells were grown on glass coverslips in six-well tissue
culture dishes. They were fixed with 4% formaldehyde in
PBS for 10 min, washed with PBS, and permeabilized
with 0.1% Triton X-100 for 2 min, washed with PBS, and
blocked with 5% BSA in PBS. The coverslips were incu-
bated with the anti-GATA3 antibody (Cell Signaling
Technology) for one hour, washed with PBS, incubated
with the secondary antibody (Alexa Fluor 568, Life Tech-
nologies, Grand Island, NY, USA) for one hour, washed
with PBS, and mounted on glass slides with mounting
medium containing 4′,6-diamidino-2-phenylindole (DAPI).
The slides were examined and photographed using a Zeiss
Axiovert 200 M microscope equipped with an Axiocam
MR digital camera controlled by AxioVision software
(Zeiss, Thornwood, NY, USA).Expression and purification of the DNA binding domain
of GATA3
DNA binding domain (DBD) of GATA3 (amino acids
261 to 371) was cloned into the pET-15b vector to pro-
duce a hexahistidine tagged fusion protein. The expression
vector was transformed into the E.coli BL21 (DE3) Codon-
Plus RIL cells, and the cells were cultured at 37°C. The
bacterial cell lysate was centrifuged at 15,000 rpm for
20 min. The supernatant was mixed gently by the batch
method with Ni-NTA beads (Qiagen, Valencia, CA, USA)
at +4°C for 30 min. The beads were washed with 5 mM
imidazole-containing buffer and GATA3-DBD was eluted
with 500 mM imidazole-containing buffer. The fractions
containing GATA3-DBD were subjected to MonoS col-
umn (GE Healthcare Life Sciences, Pittsburgh, PA, USA)
chromatography. The binding domain was eluted with a
4-column volume linear gradient of 100–600 mM NaCl.
The protein was further purified by Superdex 75 col-
umn (GE Healthcare) in a buffer containing 20 mM
Tris–HCl pH 7.5, 0.3 M NaCl, 10% glycerol, 2 mM 2-
mercaptoethanol, and 1 μM zinc sulfate. For the purifi-
cation of GATA3 mutant (D336fs) DBD, the Ni-NTA
beads were washed with the 20 mM imidazole-containing
buffer. The fractions eluted from Ni-NTA beads were dia-
lyzed against 20 mM Tris–HCl pH 7.5, 0.3 M NaCl, 10%
glycerol, 2 mM 2-mercaptoethanol, and 1 μM zinc sulfate
buffer, and concentrated with Amicon ultra-centrifuge fil-
ter (Millipore, Billerica, MA, USA).
Electrophoretic mobility shift assay (EMSA)
GATA protein (0.5, 1, 2 or 4 μM for the wild-type protein
and 0.25, 0.5, 1 or 2 μM for the mutant protein) was incu-
bated with 30 μM of 20 bp dsDNA (GATA3 recognition
motif-containing oligonucleotide AATGTCCATCTGATA
AGACG or GATA3 recognition motif-lacking oligo-
nucleotide AATGTCAAACTTTTAAGACG) in 10 μl
of a reaction buffer (28 mM Tris–HCl pH 7.5, 1 mM
dithiothreitol, 0.8 mM 2-mercaptoethanol, 120 mM NaCl,
4% glycerol, and 0.4 μM zinc sulfate). After 10 min incu-
bation at 37°C, the samples were analyzed by polyacryl-
amide gel electrophoresis, and the bands were visualized
by ethidium bromide staining. In the competitive DNA
binding assay, wild-type and mutated GATA3 DBDs were
used individually or mixed in equimolar proportion. The
reactions were performed with 15 μM of 20 bp GATA3
motif-containing oligonucleotide and 23 bp GATA3 motif-
lacking DNA (CACTTTTTAACGTAATTTACTCT).
Heparin chromatography
T47D and MCF7 nuclear extracts were prepared as de-
scribed above, using nuclear extraction buffer containing
0.4 M NaCl. The extracts were applied to a 1 ml HiTrap
Heparin Sepharose (GE Healthcare Life Sciences). The
column was eluted with a 10 ml linear gradient of NaCl
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containing 20% glycerol, 0.2 mM EDTA, 0.1 mM PMSF,
and 0.5 mM DTT. Separated fractions were analyzed by
Western blot directed against anti-GATA3.
Chromatin immunoprecipitation (ChIP) analysis
GATA3 antibody was generated in rabbits using recom-
binant 6x histidine tag-fused GATA3 full-length wild-type
protein. ChIP was performed as previously described [24]
with the following modifications. T47D or MCF7 cells
were cross-linked with 1% formaldehyde in DMEM F12
for 10 min at room temperature, quenched with gly-
cine, and then sonicated using Bioruptor (Diagenode,
Liège, Belgium) to generate 200 to 400 bp DNA frag-
ments. Immunoprecipitation was performed with GATA3
serum, and normal rabbit serum (Santa Cruz Biotech-
nology, Dallas, TX, USA) was used as a control. The
efficiency of the reaction was verified using SYBR-
green (Bio-Rad) based Real-Time PCR and primers de-
veloped by Eeckhoute et al. [14] for GATA3 binding
sites at ESR1 locus. Quantitation of precipitated DNA
was done using a standard curve with 10, 1, 0.1, and
0.01% of input DNA.
ChIP-seq library construction
DNA immunoprecipitated by GATA3 antibody in four
to five individual reactions performed at the same time
was pooled for T47D and MCF7 cells separately and
purified using MinElute PCR Purification kit (Qiagen).
Total 100 μg of ChIP or input DNA, quantified with
Qubit Fluorometer (Life Technologies, Grand Island, NY,
USA) and dsDNA High Sensitivity Assay kit (Life Tech-
nologies), was used for library construction with the help
of TruSeq RNA Sample Preparation kit (Illumina, San
Diego, CA, USA). The library was prepared following the
manufacturer’s instructions, starting with the end repair
step, and amplified with twelve PCR cycles. Two sets of
libraries (ChIP and input) were prepared for each of the
cell lines from samples immunoprecipitated on separate
occasions. The libraries were sequenced on a Genome
Analyzer IIx (Illumina) as single end 36mers.
ChIP-seq data analysis
To ensure that low quality reads were excluded from the
analysis, the raw sequence reads were filtered to remove
any entries with a mean base quality score < 20. Filtered
reads were aligned to the human genome (Genome Ref-
erence Consortium build 37/hg19; excluding haplotype
chromosomes) via Bowtie (v0.12.8 with parameters –m
1 –v 2) [25]; only reads that were mapped to an unam-
biguous ‘best’ genomic location with no more than two
mismatches were accepted. To limit PCR amplification
bias, duplicate reads were removed using MarkDupli-
cates.jar from the Picard tools package (v1.62) (http://picard.sourceforge.net). Replicate libraries were in good
agreement and were merged prior to downstream ana-
lysis. All alignments were extended at the 3’ end to a
length of 180 bases (the average expected genomic frag-
ment size for these libraries). ‘bedGraph’ files were gen-
erated from these uniquely-mapped, non-duplicated,
extended reads for visualization of aggregate genomic
coverage. Peak calling for regions of enriched GATA3
binding was performed with HOMER (v4.1; with default
parameters and “-style factor -tbp 0 -inputtpb 0”) [26]
using input (unchipped) data to model background.
Data release
GATA3 ChIP-seq data have been deposited in NCBI’s
Gene Expression Omnibus [27] and are accessible through
GEO Series accession number GSE51274 (http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE51274).
Results
Heterozygous mutation is present in GATA3 gene in
MCF7 cell line
The human GATA3 gene consists of six exons, encoding
a protein of 444 amino acids, which contains two trans-
activation domains (TA1 and TA2) and two zinc fingers
(ZnF1 and ZnF2) (Figure 1A). This gene is frequently
mutated in breast tumors. The luminal breast cancer cell
line MCF7 carries a heterozygous insertion at position
1566, which leads to a frameshift (D336fs) in the second
zinc finger and synthesis of a truncated GATA3 protein
[23] (Figure 1B). We confirmed the presence of guanine
insertion in GATA3 gene in our MCF7 stock and used a
second luminal breast cancer cell line, T47D, wild-type
for GATA3, as a control for our experiments. While T47D
cells expressed only wild-type GATA3 protein (approxi-
mately 48 kDa), MCF7 cells contained both the full length
GATA3 as well as a truncated protein of approximately
37 kDa (Figure 1C). Steady state levels of this truncated
protein in MCF7 cells were significantly higher than the
full-length GATA3 in the same cells (Figure 1C).
Truncated GATA3 protein is easily released from the
nucleus
We used T47D and MCF7 cell lines to study the effect of
the frameshift mutation in GATA3 gene on the properties
of the protein. Immunofluorescence staining was employed
to verify cellular localization of GATA3 in T47D and
MCF7 cells, demonstrating nuclear localization, regardless
of the mutation status (Figure 2A). Subcellular fraction-
ation with extraction buffer containing between 0.1 and
0.8 M NaCl, demonstrated that wild-type GATA3 was ex-
tracted efficiently from nuclei at moderate salt concentra-
tion (0.4 M NaCl) from nuclei in T47D cells (Figure 2B).
The full-length protein behaved in a similar manner in
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Figure 1 Structure of GATA3 transcription factor. A) GATA3 consists of 444 amino acids, which contain two transactivation domains (TA1 and
TA2) and two zinc fingers (ZnF1 and ZnF2). B) The second zinc-finger binds to the canonical GATA motif, WGATAR, and the residues marked in
blue are responsible for contact with DNA [10,32]. MCF7 breast cancer cell line carries a heterozygous mutation, which leads to a frameshift
(D336fs) in the second zinc finger and synthesis of a truncated protein. Figure modified from Ali et al. [21] and Ho et al. [10]. C) Expression of wild
type (WT) and mutated (Mut) GATA3 in MCF7 and T47D cells. MDA-MB-231, breast cancer cell line, negative for GATA3 was used as a control.
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chromatin with extraction buffer containing even the low-
est NaCl concentration (0.1 M). The truncation mutant
was present in the cytoplasmic fraction as well, suggesting
that a pool of mutant protein is nuclear, but has impaired
interaction with chromatin and is easily released from the
nucleus.
The second-zinc finger frameshift mutation stabilizes
GATA3 protein
The increased steady-state abundance of the truncated
GATA3 mutant in MCF7 (Figure 1C, also [23]) suggested
that the mutation impacts stability. To test this hypoth-
esis, T47D and MCF7 cells were treated with a translation
inhibitor, cycloheximide and GATA3 abundance was mea-
sured over time using immunoblot of whole cell lysates.
Over the course of eight hours, levels of wild-type GATA3
in T47D cells decreased, with a significant reduction vis-
ible four hours after the treatment (Figure 3A, Additional
file 1: Figure S1). In contrast, both wild-type and mutant
GATA3 in MCF7 exhibited greater stability, with half
lives in excess of 8 hours (Figure 3A, Additional file 1:
Figure S1), suggesting that the mutant protein titrates
out a factor integral to GATA3 turnover.
Protein stability controlled by action of the 26S prote-
asome is integral to the biology of ERα [28], which is
found in close proximity to GATA3 at many genomiclocations in breast cancer cells [17,18]. Inhibition of
ubiquitin-proteasome pathway stabilizes GATA3 in devel-
oping T cells [29]. To determine whether GATA3 protein
turnover is regulated in a similar, proteasome-dependent
manner in breast cancer, we treated cells with cyclohexi-
mide and a proteasome inhibitor, MG132. In both T47D
and MCF7 cells, proteasome inhibition alleviated the ef-
fect of translation inhibition on wild-type and, to a lesser
degree, mutated GATA3 (Figure 3B). These data indicate
that GATA3 is regulated at the protein level by the pro-
teosome and that the cancer-specific mutation results in
increased protein stability.
GATA3 mutation uncouples turnover from the hormone
response
GATA3 is tied to ERα through a positive cross-regulatory
loop [14] and ERα turnover by the proteosome is intim-
ately connected to ligand binding [28]. As GATA3 protein
stability was regulated in a manner similar to ERα, we hy-
pothesized that its stability might also be influenced by es-
tradiol and that the frameshift mutation might impact
protein-level regulation of GATA3 by hormone. Addition
of estradiol to hormone starved cells results in cyclic vari-
ation of ERα levels, we chose a time point at which this
cycling has stabilized (24 hours). Treating hormone-
starved T47D or MCF7 cells with estradiol led to down-
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Figure 2 Cellular localization of wild-type and mutated GATA3 in breast cancer cells. A) Immunofluorescence staining of T47D and MCF7
cells. Scale bar corresponds to 20 μm. B) Subcellular fractionation of T47D or MCF7 cell extracts in 0.1-0.8 M NaCl. Input – whole cell lysate,
CF – cytoplasmic fraction, NE – nuclear extract.
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tradiol, mirroring ERα. In contrast, both wild type and
truncated GATA3 in MCF7 were only moderately affected
by hormone. FOXA1, an essential determinant of ERα ex-
pression [30] and a frequent binding partner of ERα and
GATA3 [17,31], decreased in abundance following estra-
diol treatment in T47D, although not to the same extent
as GATA3 and ERα (Figure 4A, B). In MCF7, hormone
had little to no impact on FOXA1 levels. These results
suggest that the stability of three DNA binding transcrip-
tion factors integral to the transcriptional response to es-
trogen in luminal breast cancer cells, exhibits altered
turnover downstream of estrogen upon mutation of one
allele of GATA3.
Because the truncating mutation alters GATA3 protein
level following hormone treatment, we asked whetherthe action of estrogen antagonists was likewise affected
by this mutation. We treated cells grown in normal
conditions (media plus FBS) with the ERα antagonist,
ICI 182,780 (ICI). As expected, ERα expression was re-
duced in both cell lines (Figure 4C). While wild-type
GATA3 protein levels were reduced following antagon-
ist treatment in both T47D and MCF cells, the level of
mutated GATA3 in MCF7 cells did not change. FOXA1
expression was not affected by ICI (Figure 4C). The
GATA3 mRNA level remained mostly unaffected in
cells treated with estradiol or ICI (Additional file 1:
Figure S2). These experiments demonstrate that the
truncation mutation in GATA3 stabilizes the protein in
the face of agonist or antagonist binding by ERα, thus
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Figure 3 Protein stability of wild-type and mutated GATA3. A) T47D and MCF7 cells were treated with cycloheximide (CHX) or DMSO
(Control) and collected at 2, 4, 6 and 8 hours. B) T47D and MCF7 cells were treated with cycloheximide (CHX), MG-132 (MG), or DMSO (Control)
and collected 8 hours later.
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The frameshift mutation present in GATA3 in MCF7 af-
fects the second zinc finger, which is responsible for DNA
binding [32]. We employed electrophoretic mobility shift
assays (EMSA) to interrogate the DNA binding capacity
of mutated GATA3 protein. By titrating the recombinant
DNA binding domain (DBD) of wild-type GATA3 [32],
we demonstrated a shift from the free GATA-motif-
containing oligonucleotide to a specific, protein bound
complex (Figure 5A, lanes 1–5). In contrast, the mutant
GATA3 DBD was able to bind DNA to a lesser degree
and only at high concentrations of recombinant protein
(Figure 5B, lanes 1–5). To assess whether the wild-type
and mutant DBD protein fragments could heterodimer-
ize on DNA, we mixed recombinant wild-type and
mutated DBDs in a competitive assay with GATA motif-
containing and GATA motif-lacking oligonucleotide.We did not observe any evidence of a complex with al-
tered mobility following addition of mutant GATA3
DBD (Figure 5C, lanes 1–4 and 8–10). A similar experi-
ment without competitor DNA had identical results
(data not shown).
To further characterize the ability of endogenous GATA3
to bind DNA, we utilized heparin, a glycosaminoglycan
structurally similar to nucleic acids. Nuclear extracts ob-
tained from T47D and MCF7 cells were partially purified
through ion exchange chromatography, applied to a hep-
arin column, and eluted with a linear gradient of NaCl.
The peak of full-length GATA3 from T47D eluted between
0.57 and 0.71 M NaCl (Figure 6A). In MCF7 both full-
length and truncated GATA3 were eluted in the same
range of salt, 0.51-0.63 M (Figure 6B), indicating a poten-
tial for formation of GATA3 wild-type/mutant heterodi-











































Figure 4 Protein stability of GATA3 in cells treated with ERα agonist or antagonist. A) T47D and MCF7 cells were grown in hormone-
depleted conditions and then treated, at Time 0, with 50 nM 17β-estradiol (E2) for 24 hours. B) Quantification of Western blot signal intensity in
panel B. C) T47D and MCF7 cells were treated with 100 nM ICI 182,780 (ICI), an estrogen receptor antagonist, for 24 hours.
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To analyze the genomic location of GATA3 transcription
factor in T47D and MCF7 cells, we performed chromatin
immunoprecipitation (ChIP) on asynchronous cultures.
We first established a robust ChIP assay using polyclonal
sera raised against full length recombinant GATA3 (which
recognizes both full-length and mutant proteins). We
assessed GATA3 enrichment at published positive con-
trol loci [14] using PCR for detection (Additional file 1:
Figure S3). ChIP DNA was used to prepare standard
libraries for massively parallel sequencing under condi-
tions that preserve enrichment for the positive control
regions (Additional file 1: Figure S4). Sequencing was
performed on two biological replicates from T47D and
MCF7 cells, resulting in 33-45×106 reads per library.
Following quality control, mapping to unique positionsin the human genome, and deduplication, 37-59% reads
were retained (Additional file 2: Table S1). Sequencing
reads from the two libraries from each cell line were
merged (Additional file 2: Table S2). The HOMER algo-
rithm identified 11,593 enriched regions (peaks) in T47D
cells and 21,173 in MCF7 cells. Total 6,336 of these peaks
overlapped by at least 1 bp (Figure 7A). Selected ChIP-seq
peaks were validated using Real-Time PCR (Additional
file 1: Figure S5).
We explored the similarities in ChIP-seq between the
two cell lines in terms of location relative to genomic fea-
tures and intensity. In spite of the difference in number of
GATA3 enriched regions, peak distribution relative to the
closest transcription start site (TSS) was similar in T47D
and MCF7 cells (Figure 7B). T47D cells had modestly
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Figure 5 DNA binding ability of wild-type and mutated GATA3. Electrophoretic Mobility Shift Assay (EMSA) was performed using
recombinant A) wild-type GATA3 DNA binding domain (DBD) or B) mutated GATA3-DBD. Equivalent molar amounts of wild-type and mutant
protein, assessed by Coomassie blue stained SDS-PAGE, were used. C) In a competitive assay, an equimolar mix of wild-type and mutated
DBD proteins was used. To test protein ability to bind DNA, GATA3 motif-containing oligonucleotides (GATA +) and GATA3 motif-lacking
oligonucleotides (GATA-) were used. WT – wild-type, Mut – mutated GATA3.
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http://www.biomedcentral.com/1471-2407/14/278to +2 kb from TSS (Figure 7C, D). When the peaks
were sorted by ChIP-seq signal, distribution in both
cell lines was almost indistinguishable for peaks
within 10 kb from the closest TSS as well as for those
not associated with TSS – meaning that high-intensity
peaks were distributed in a similar manner (Figure 7E).
While these general indicators of pattern of enrichment
appeared highly similar across the two cell lines, we ob-
served a difference in overall signal intensity at peaks.
Regardless of their localization relative to TSSs, bins of
peaks in MCF7 exhibited a broader range of signal in-
tensity than comparable bins in T47D (Figure 7F). This
relationship was further corroborated by scrutiny of
mean and median values for peaks grouped according
to distance from TSS, where MCF7 invariably had
higher mean and median values. At a gross level, the
overall pattern of association of GATA3 with the gen-
ome appeared highly similar between the two cell lines.
However, peak signal intensity after normalization for
read depth was higher in MCF7 than in T47D.Assigning GATA3 peaks to the closest transcription
start site (TSS) resulted in 4524 genes within 50 kb in
T47D and 6934 in MCF7, including 3011 genes overlap-
ping between both cell lines (Table 1, Additional file 3:
Tables S3 and S4). Ingenuity Pathway Analysis of genes
associated with genomic regions enriched for GATA3
binding indicated that cell cycle, death and survival,
growth and proliferation, movement, and development
were the top functional categories related to GATA3 pres-
ence in T47D cells (Additional file 1: Figure S6). The top
molecular and cellular functions in MCF7 were similar
and included cellular growth and proliferation, develop-
ment, movement, death and survival, and cell to cell
signaling and interaction (Additional file 1: Figure S7). A
more detailed analysis focusing on genes involved in
mammary tissue differentiation, breast cancer subtype de-
termination, or estrogen response [31,33-35], showed that
although GATA3 was present near 20-60% of TSSs, there
was no enrichment detected when compared to the ex-
pected occupancy in a given functional group. Also, there
AB
0.57 M NaCl 0.71 M NaCl





Fractions eluted with increasing NaCl concentration
Figure 6 Biochemical characterization of wild-type and mutant GATA3 using a nucleic acid analog. Nuclear extracts were prepared from
A) T47D and B) MCF7 cells and applied to heparin sepharose. The column was eluted with linear gradient of NaCl concentration from 0.1 to 1 M.
The separated fractions were analyzed by Western blot directed against GATA3.
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http://www.biomedcentral.com/1471-2407/14/278were no major differences in the tested datasets between
GATA3 transcription factor binding in T47D and MCF7
cells (Additional file 1: Figures S8-S10).
There were, however, individual genes that differed
substantially in GATA3 enrichment between cell lines
(Additional file 4: Table S5). The progesterone receptor
(PGR) is an example of an individual locus displaying a
difference in GATA3 occupancy between cell lines, with
T47D featuring seven peaks spanning over 200 kb and
MCF7 cells containing only one peak in the same region
(Figure 8). The biologic significance of this finding re-
mains unclear, although the reduced expression of PGR in
MCF7, as compared to T47D, may be reflective of alter-
ations in GATA3 binding (Additional file 1: Figure S11).
Using a mobility shift assay, we established that the
frameshift mutation present in GATA3 in MCF7 impairs
the protein’s ability to bind DNA. To test whether the
mutation affects the capacity to specifically recognize
DNA sequence in the genome, we evaluated the fre-
quency of occurrence of the GATA3 canonic recognition
motif, WGATAR within the ChIP-seq peaks. The propor-
tion of GATA3 peaks containing the recognition motif in
T47D and MCF7 cells was essentially identical - 71.4%
and 72.7%, respectively (Table 2). We explored whether
binning peaks in several different ways impacted this simi-
larity and found that no matter how we grouped the
peaks, the frequency of peaks containing the consensus
GATA3 element was consistent between the two cell lines
(Additional file 1: Figure S12). These data suggest that themutation in MCF7 does not significantly change the bind-
ing site preference of GATA3 in the context of chromatin.
Discussion
Large-scale genome sequencing projects have provided,
and continue to provide, volumes of information on the
mutational landscape of cancers. A current challenge for
cancer biologists is to investigate the emerging genomic
data in a mechanistic context, establishing the relationship
of specific mutations to tumor biology and informing on
clinical parameters including aggressiveness, response to
therapy, and potential for metastasis. Here, we have initi-
ated an attempt to address the mechanistic basis by which
mutations in the transcription factor GATA3 may provide
a growth advantage to breast cancer cells. The Cancer
Genome Atlas Network (TCGA) recently reported a com-
prehensive study of human breast cancer: tumors from
507 patients were analyzed on multiple high information
content platforms: whole exome sequencing, DNA copy
number arrays, DNA methylation, mRNA array and se-
quencing, microRNA sequencing and reverse-phase pro-
tein arrays [1]. Somatic mutations in GATA3 occurred in
58 cases (10.7%), predominantly in luminal A and B can-
cer subtypes, an additional 12 samples displayed copy
number alterations (http://www.cbioportal.org). Strikingly,
while mutations of GATA3 in the congenital disorder
HDR syndrome are found throughout the protein [22],
breast cancer specific mutations occur almost exclusively
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Figure 7 Genomic location of wild-type and mutated GATA3 transcription factor in T47D and MCF7 cell lines. A) Number of GATA3
ChIP-seq peaks in T47D and MCF7 cells. B) GATA3 peak distribution relative to distance from the closest transcription start site (TSS) in T47D and
MCF7 cells. C) GATA3 ChIP-seq peak distribution within 10 kb from the closest TSS in T47D and MCF7 cells. D) GATA3 ChIP-seq peak distribution
within 100 kb from the closest TSS in T47D and MCF7 cells. E) GATA3 occupancy enriched regions sorted by increasing ChIP-seq signal. Peaks
were divided into peaks not associated with a TSS (no TSS) and peaks within 1 kb or 10 kb from the closest TSS (TSS in 1 or 10 kb). y-axis is scaled
to % of maximal for given cell line RPKM (reads per kilobase per million). F) ChIP-seq signal range in T47D and MCF7 cells. Box represents 25% to
75% of the range and whiskers are 5% to 95%. Black dot is median and yellow dot is mean value. Legend - see E).
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http://www.biomedcentral.com/1471-2407/14/278regulatory roles for the carboxyl terminus of GATA3 and
that impairment of these functions can provide a growth
advantage to cancer cells.
Careful scrutiny of the TCGA mutation data revealed
that six mutations were localized in the second zinc fin-
ger and five of them were frameshifts, similar to the mu-
tation in MCF7 [23], making MCF7 a useful model to
study a clinically relevant phenomenon. We confirmed
the presence of a heterozygous guanine insertion in the
fifth exon of GATA3 in the MCF7 genome and showedthat although both full-length and truncated proteins
were expressed, the mutated protein was present in the
cells at a higher level. The D336 frameshift does not
affect the N-terminal and C-terminal sequences flanking
ZnF1 that are required for nuclear localization [22] and
GATA3 proteins localized to the nucleus of MCF7 cells.
Mutations in GATA3 ZnF2 impair DNA binding [20-22]
suggesting that the same effect could be expected for
MCF7-specific mutation. The biochemical fractionation
assay identified a pool of truncated protein very loosely
Table 1 Number of genes associated with GATA3
transcription factor binding in T47D and MC7 breast
cancer cell lines within 10 and 50 kb from the closest
transcription start site (TSS)
Cell line Number of genes*




*Genes may contain more than one GATA3 peak within specified distance
from TSS.
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http://www.biomedcentral.com/1471-2407/14/278associated with chromatin (Figure 2B). However, the gel
shift assay demonstrated that truncated GATA3 could
bind DNA selectively, albeit with decreased affinity
compared to wild-type (Figure 5). Consistent with the
documented capacity of GATA3 to self-associate and to
dimerize on DNA [32], we observed a pool of mutant
protein that exhibited similar chromatin binding prop-
erties to wild-type GATA3. The data are consistent with
formation of heterodimers between mutant and wild-
type GATA3, potentially altering the association of the
protein with its recognition elements in the genome.
ChIP-seq was utilized to assess the degree of overlap
of GATA3 across the two cell lines used in our study.
Surprisingly, the number of binding sites detected in
MCF7 was substantially higher than in T47D cells. In
spite of the large difference in genomic occupancy, de-
tailed analysis of genes associated with GATA3 binding
failed to identify any major functional differences between
binding profiles in T47D and MCF7 cell lines (Additional
file 1: Figure S6-S10). We speculated that the increased
number of GATA3-enriched regions in MCF7 genome
could have been due to compromised ability of the trun-
cated protein to recognize the specific GATA binding


















Figure 8 Transcription factor GATA3 binding at progesterone receptopeaks containing the WGATAR motif was nearly identical
in binding regions identified in T47D and MCF7 cells, as
well as in cell-line specific regions (Table 2). This finding
suggested that the heterozygous mutation did not affect
binding specificity in MCF7 cells.
Although the number of GATA3 peaks was considerably
lower in T47D than in MCF7 cells, progesterone receptor
gene was an example of a locus featuring a greater num-
ber of bound regions in T47D than in MCF7. Remarkably,
lack of PGR expression, as determined by immunohisto-
chemical staining, was a common denominator for all five
patients in the TCGA database carrying a frameshift mu-
tation in ZnF2 of GATA3 (http://www.cbioportal.org).
Even though both T47D and MCF7 cell lines are classified
as PGR and ERα positive, and belong to luminal A breast
cancer subtype [36], MCF7 has been also used as a model
for luminal B subtype [37]. The luminal B subtype is the
more aggressive form of ERα-positive breast cancer that is
less responsive to endocrine therapy [38]. It is character-
ized by increased expression of proliferation-related genes
and lower expression of ER-dependent genes, including
PGR [38,39]. In our model system, PGR mRNA level was
approximately 20-fold lower in MCF7 than in T47D cells
(Additional file 1: Figure S11). Loss of PGR expression is
often considered as a marker for the gain of hormone-
independent growth properties by ERα-positive breast
cancers, through increased cross-talk between ERα and
growth factor signaling pathways [38,40]. In addition, the
normal balance of the two known PGR isoforms, A or B,
impacts biological properties of tumors [41].
Comparison of the biochemical properties of mutated
GATA3 with wild type protein present in the T47D cell
line demonstrated an increased half-life of truncated
GATA3 in normal growth conditions and in response to
ERα agonist and antagonist (Figures 3 and 4). GATA3





r (PGR) locus in T47D and MC7 cells.
Table 2 Frequency of GATA3 recognition motif WGATAR
in GATA3-peaks identified by ChIP-seq in T47D and MCF7
cells
GATA3 peaks All Peaks containing
WGATAR motif
Number Percent [%]
T47D 11593 8281 71.4
T47D peaks overlapping with MCF7 6336 4655 73.5
T47D-specific 5257 3626 69.0
MCF7 21173 15392 72.7
MCF7 peaks overlapping with T47D 6336 4590 72.4
MCF7-specific 14837 10802 72.8
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http://www.biomedcentral.com/1471-2407/14/278ERα, where rapid turnover of the receptor upon ligand
binding is based on the ubiquitin-proteasome pathway
[28]. GATA3 is required for estrogen stimulation of cell
cycle progression in breast cancer cells [14] and we
showed that this truncating mutation present in MCF7
genome uncouples protein level regulation from hormonal
signaling.Conclusions
These findings strongly suggest that the carboxyl terminus
of GATA3, a mutational hotspot in breast cancer, confers
regulation on protein levels through as yet undefined
mechanisms, resulting in increased stability of transcription
factors resident on critical response elements in the breast
cancer genome. We predict that mutations in GATA3 with
similar characteristics to the mutation in MCF7 likely con-
fer a growth advantage, particularly in pre-menopausal
women, and are likely to occur early in tumor evolution.Additional files
Additional file 1: Figure S1. Quantification of Western blot signal
intensity for full-length and truncated GATA3 protein in T47D and MCF7
cells treated with DMSO (Vehicle) or cycloheximide (CHX) over the course
of eight hours. Figure S2. GATA3 mRNA level in T47D and MCF7 cells
treated with estradiol (E2) or ICI 182,780 (ICI). Figure S3. GATA3
enrichment determined by Real-Time PCR in ChIP reactions pooled for
ChIP-seq library preparation. Figure S4. GATA3 enrichment in
PCR-amplified ChIP-seq library in positive (ESR1 Enh1) and negative
(ESR1 -6.9 kb) control regions located upstream from estrogen receptor
transcription start. Figure S5. Real-Time PCR validation of GATA3 binding
in T47D and MCF7 genome determined by ChIP-seq. Figure S6.
Functional classification of genes located within 50 kb from a GATA3
ChIP-seq peak in T47D cells. Figure S7. Functional classification of genes
located within 50 kb from a GATA3 ChIP-seq peak in MCF7 cells. Figure S8.
GATA3 ChIP-seq peak presence in T47D and MCF7 cells within 10 kb from
TSS of genes involved in normal mammary cell commitment and
differentiation. Figure S9. GATA3 ChIP-seq peak presence in T47D
and MCF7 cells within 50 kb from TSS of estrogen-responsive genes.
Figure S10. GATA3 ChIP-seq peak presence in T47D and MCF7 cells
within 50 kb from TSS of genes differentially expressed in different
molecular subtypes of breast cancer. Figure S11. Progesterone receptor
(PGR) expression in T47D and MCF7 cells treated with GATA3 siRNA (Error
bars represent standard deviation; n=2) or infected with GATA3 adenovirus(Adv) (n=1). Figure S12. Frequency of GATA3 recognition motif, WGATAR,
in GATA3 ChIP-seq peaks located within 10 kb.
Additional file 2: Table S1. Number of reads in each sequencing run
for GATA3 ChIP-seq in T47D and MCF7 cell lines. Table S2. Number of
reads in merged samples for two replicates of GATA3 ChIP-seq in T47D
and MCF7 cell lines.
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border. Table S4. GATA3 ChIP-seq peaks identified in MCF7 cell line.
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